Capricor Deramiocel Faces FDA AdComm July 29 for DMD

Update July 29, 2026: The CTGTAC voted 9-3 against deramiocel, siding with FDA staff that HOPE-3 did not provide substantial evidence of effectiveness. See our coverage: FDA Panel Votes 9-3 Against Capricor Deramiocel for DMD.

Price update August 1, 2026 (Polygon): CAPR closed at $3.85 on July 31 (Polygon), down from $4.19 on July 30 and down 80.6% from the $19.83 article reference price. The stock continues to bleed after the 9-3 AdComm vote against deramiocel. The August 22 PDUFA now leans toward rejection. See our AdComm vote coverage.

Update August 27, 2026: CAPR closed at $9.36 on August 26 (Polygon), up 36.8% from the $6.84 August 20 close. Oppenheimer upgraded the stock on August 25 following the FDA’s confirmation that deramiocel’s PDUFA is extended to November 22 (upper-limb-only claim).

Update August 21, 2026: The August 22 PDUFA is one day away (a Saturday; the FDA may act Friday August 21 or Monday August 24). CAPR closed at $6.84 on August 20 (Polygon), up 77% from the $3.85 July 31 close after surging 67% after-hours on August 13 when the company outlined a “clearer regulatory path” (a potential pivot to an upper-limb indication). STAT News nonetheless reported August 20 that the FDA is “heading for” rejection. See our AdComm vote coverage.

Update August 22, 2026: On August 21, Capricor confirmed it will submit a BLA amendment narrowing deramiocel’s proposed indication to upper-limb dysfunction only — and the FDA is expected to extend the August 22 PDUFA once it receives the amendment. See our amendment coverage.

Update August 25, 2026: The FDA confirmed on August 24 that it extended deramiocel’s PDUFA to November 22, 2026, classifying the upper-limb-only amendment as a major (three-month) extension. No approval-or-CRL decision lands until then. See our amendment coverage.

Since this article was published (July 24): FDA briefing documents released July 27 disputed Capricor’s claim that HOPE-3 met its primary endpoint, citing post-hoc changes to the statistical analysis plan and blinding concerns. CAPR shares crashed 65% from $19.83 to $6.53 on July 27. See our updated coverage: FDA Disputes Capricor Deramiocel Phase 3 Results, Shares Plunge 65%.

Capricor Therapeutics (CAPR) faces a July 29 FDA advisory committee meeting for deramiocel, an allogeneic cell therapy for cardiomyopathy in Duchenne muscular dystrophy. The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee will vote on the application, with a PDUFA date of August 22.

An advisory committee, or AdComm, is a panel of outside experts that reviews data and makes a non-binding recommendation to the FDA. The agency typically follows the committee’s vote but is not required to.

The rescinded CRL

The FDA previously issued a Complete Response Letter for this BLA, then rescinded it. A CRL is an FDA letter explaining why a drug application cannot be approved as submitted. The rescission signals that the agency’s concerns shifted, though the FDA has not publicly detailed what changed.

That unusual reversal frames the AdComm as a high-stakes moment. If the committee votes favorably, it would clear a path to approval on August 22. A negative vote would be a significant setback given the prior CRL history.

What deramiocel does

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells, a cell therapy with immunomodulatory and anti-fibrotic properties. Clinical studies showed preservation of cardiac and skeletal muscle function in DMD patients.

Duchenne muscular dystrophy is a severe, X-linked genetic disorder causing progressive muscle degeneration affecting skeletal, respiratory, and cardiac muscles. Cardiomyopathy is the leading cause of death in DMD patients. A cardiac-specific therapy would address the deadliest complication of the disease.

If approved, deramiocel would be the first cell therapy for DMD cardiomyopathy.

Market context

CAPR closed at $19.83 on July 23, up from $18.51 at the open, on volume of 2.01 million shares. The market cap sits near $1.1 billion. That valuation is built almost entirely on the deramiocel approval thesis.

For context on how binary catalysts move small-cap biotech stocks, see our coverage of Arrowhead’s plozasiran Phase 3 readout.

Risks

The prior CRL indicates the FDA had concerns about the data. Cell therapies face manufacturing and consistency questions, and allogeneic cell products carry additional challenges around donor variability and immune compatibility. The AdComm panel may press on durability of effect and whether the clinical data adequately supports efficacy.

DMD is also a crowded indication. Sarepta’s gene therapy Elevidys (delandistrogene moxeparvovec) is approved for ambulatory patients, and standard-of-care includes corticosteroids. Deramiocel targets the cardiac complication specifically, which differentiates it, but the competitive picture complicates the commercial outlook.

What to watch next

The July 29 committee vote has now resolved: the CTGTAC voted 9-3 against deramiocel. The next binary event is the August 22 PDUFA, which is now imminent (one day away as of August 21). Given the 9-3 negative vote, the FDA’s own briefing documents, and STAT’s August 20 report that the agency is “heading for” rejection, approval is unlikely — though Capricor’s August 13 pivot to a potential upper-limb indication is the one wild card.

FDA advisory committee meeting announcement | Capricor press release